Madrigal Pharmaceuticals (stock symbol: MDGL) Logo in transparent PNG format

Madrigal Pharmaceuticals Logo large

Madrigal Pharmaceuticals Logo icon format

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

  • Website domain: madrigalpharma.com
  • Employees: 71
  • Marketcap: $1.10 Billion USD

Page last updated on:

October 3rd, 2020

Categories: